Lidcombe Program telehealth treatment for children 6-12 years of age: A Phase II trial

被引:2
|
作者
Johnson, Georgina [1 ]
Onslow, Mark [2 ]
Carey, Brenda [2 ]
Jones, Mark [3 ]
Kefalianos, Elaina [1 ,4 ]
机构
[1] Univ Melbourne, Dept Audiol & Speech Pathol, 550 Swanston St, Carlton, Vic 3053, Australia
[2] Univ Technol Sydney, Australian Stuttering Res Ctr, Ultimo, NSW, Australia
[3] Bond Univ, Inst Evidence Based Healthcare, Robina, Qld, Australia
[4] Murdoch Childrens Res Inst, Speech & Language Grp, Parkville, Vic, Australia
关键词
School-age; Stuttering; Treatment; SELF-REPORTED EXPERIENCE; SOCIAL ANXIETY DISORDER; PSYCHOMETRIC PROPERTIES; FOLLOW-UP; STUTTER; IMPACT; SPEECH; PARENT; INTERVENTION; SATISFACTION;
D O I
10.1016/j.jfludis.2024.106057
中图分类号
R36 [病理学]; R76 [耳鼻咽喉科学];
学科分类号
100104 ; 100213 ;
摘要
Background: For children older than 6 years who stutter, there is a gap in clinical research. This is an issue for speech-language pathologists because the tractability of stuttering decreases and the risk of long-term psychological consequences increase with age. Purpose: To report a Phase II trial of a telehealth version of the Lidcombe Program with school-age children. Methods: Participants were 37 children who stuttered, 6-12 years of age, from Australia, New Zealand, Hong Kong, and Singapore. Parents were trained by video telehealth how to deliver the Lidcombe Program to their child. Primary and secondary outcomes were stuttering severity and psychosocial functioning measured pre-treatment and at 6 months and 12 months after starting treatment. Parents submitted two 10-minute recordings of their child speaking in conversation, and three measures of anxiety, impact of stuttering, and communication attitude. Results: Six months after starting treatment, seven children (18.9%) attained Lidcombe Program Stage 2 criteria, 25 children (67.6%) showed a partial response to treatment, and five children (13.5%) showed no response. By 12 months, 12 children (32.4%) had reached Stage 2 criteria. Psychosocial improvements were observed 6 and 12 months after starting treatment. Conclusions: The Lidcombe Program may eliminate or nearly eliminate stuttering for about one third of children 6-12 years of age. Randomized controlled trials with this age group involving the Lidcombe Program are warranted. In the interim, the Lidcombe Program is a clinical option clinicians can implement with this age group to reduce stuttering and its psychosocial impacts.
引用
收藏
页数:13
相关论文
共 36 条
  • [21] A Study of Sleep Quality and Quality of Life in Children with Atopic Dermatitis between 6 and 12 Years of Age
    Kallan, Febin
    Pillai, Rathish T.
    Hijaz, P. T.
    Simi, P. S.
    Nair, Rakhee V.
    INDIAN JOURNAL OF PAEDIATRIC DERMATOLOGY, 2023, 24 (04) : 261 - 267
  • [22] Prediction of asthma in children at 6 and 12 years of age:: Perth infant asthma follow-up study
    Le Souëf, P
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2002, 13 : 44 - 46
  • [23] Treatment for behavioral insomnia in young children with neurotypical development under 6 years of age: A systematic review
    Lecuelle, Florian
    Leslie, Wendy
    Gustin, Marie-Paule
    Franco, Patricia
    Putois, Benjamin
    SLEEP MEDICINE REVIEWS, 2024, 74
  • [24] Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial
    Hedrick, JA
    Barzilai, A
    Behre, U
    Henderson, FW
    Hammond, J
    Reilly, L
    Keene, O
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (05) : 410 - 417
  • [25] The effectiveness of a therapeutic parenting program for children aged 6-11 years with behavioral or emotional difficulties: Results from a randomized controlled trial
    Axford, Nick
    Bjornstad, Gretchen
    Matthews, Justin
    Heilmann, Sarah
    Raja, Anam
    Ukoumunne, Obioha C.
    Berry, Vashti
    Wilkinson, Tom
    Timmons, Luke
    Hobbs, Tim
    Eames, Tim
    Kallitsoglou, Angeliki
    Blower, Sarah
    Warner, Georgina
    CHILDREN AND YOUTH SERVICES REVIEW, 2020, 117
  • [26] Long-term (68 weeks) administration of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: efficacy and safety data from a phase III study
    Igarashi, Atsuyuki
    Katsunuma, Toshio
    Nagano, Yuko
    Komazaki, Hiroshi
    BRITISH JOURNAL OF DERMATOLOGY, 2025, : 837 - 844
  • [27] PLAYgrounds: Effect of a PE playground program in primary schools on PA levels during recess in 6 to 12 year old children. Design of a prospective controlled trial
    Janssen, Mirka
    Toussaint, Huub M.
    Van Willem, Mechelen
    Verhagen, Evert A. L. M.
    BMC PUBLIC HEALTH, 2011, 11
  • [28] Improved Neurodevelopmental Outcomes at 5.5 Years of Age in Children Who Received Bovine Milk Fat Globule Membrane and Lactoferrin in Infant Formula Through 12 Months: A Randomized Controlled Trial
    Colombo, John
    Harris, Cheryl L.
    Wampler, Jennifer L.
    Zhuang, Weihong
    Shaddy, D. Jill
    Liu, Bryan Y.
    Wu, Steven S.
    JOURNAL OF PEDIATRICS, 2023, 261
  • [29] A Phase 3, Single-arm Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through <18 Years of Age
    Meyer, Jay
    Silas, Peter
    Ouedraogo, G. Laissa
    McElwee, Kathleen
    Keep, Georgina
    Trammel, James
    Peng, Yahong
    Scully, Ingrid L.
    Gruber, William C.
    Scott, Daniel A.
    Watson, Wendy
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2024, 43 (06) : 574 - 581
  • [30] Nutritional treatment of children 6–59 months with severely low weight-for-age z-score: a study protocol for a 3-arm randomized controlled trial
    Suvi T. Kangas
    Césaire T. Ouédraogo
    Moctar Tounkara
    Bareye Ouoluoguem
    Issa Niamanto Coulibaly
    Alhousseyni Haidara
    Niele Hawa Diarra
    Koniba Diassana
    Zachary Tausanovitch
    Christian Ritz
    Jonathan C. Wells
    André Briend
    Mark Myatt
    Elizabeth Radin
    Jeanette Bailey
    Trials, 25